Key result
In patients receiving intravenous thrombolysis for acute ischemic stroke, atrial fibrillation was associated with a lower proportion of excellent functional outcomes at 90 days compared to those without atrial fibrillation.
Why the study?
The efficacy and safety of intravenous thrombolysis for acute ischemic stroke with atrial fibrillation remained controversial.
Does intravenous thrombolysis improve functional outcomes and reduce mortality in acute ischemic stroke patients with atrial fibrillation compared to those without AF or those not receiving thrombolysis?
Meta-Analysis (n=8,509)
Does intravenous thrombolysis improve functional outcomes and reduce mortality in acute ischemic stroke patients with atrial fibrillation compared to those without AF or those not receiving thrombolysis?
Answers are grounded in this paper and cite their sources.
Intravenous thrombolysis in acute ischemic stroke patients with atrial fibrillation carries a higher risk of symptomatic intracranial hemorrhage without a clear improvement in 90-day functional prognosis compared to those not receiving thrombolysis.
BACKGROUND: The efficacy and safety of intravenous thrombolysis (IVT) for acute ischemic stroke with atrial fibrillation (AF) is still controversial. METHODS: We conducted a meta-analysis of all relevant studies, retrieved through systematic search of PubMed, Embase, and Cochrane databases up to December 31, 2019. Modified Rankin Scale (mRS) scores of 0-1 at 90 days, mRS of 0-2 at 90 days, overall mortality, and incidence of symptomatic intracranial hemorrhage (sICH) were collected as outcome measures. Fixed- and random-effects meta-analytical models were applied, and between-study heterogeneity was assessed. RESULTS: A total of 8509 patients were enrolled in 18 studies. A comparison of IVT treatment in AF versus non-AF patients showed that AF was associated with a significantly lower proportion of patients with mRS of 0-1 (24.1% vs. 34.5%; OR 0.59; 95% CI 0.43-0.81; P < 0.001), mRS of 0-2 (33.6% vs. 47.8%; OR 0.55; 95% CI 0.43-0.70; P < 0.001), as well as significantly higher mortality (19.4% vs. 11.5%; OR 2.05; 95% CI 1.79-2.36; P < 0.001) and higher incidence of sICH (6.4% vs. 4.1%; OR 1.60; 95% CI 1.27-2.01; P < 0.001). A comparison of AF patients who were subjected or not to IVT showed that thrombolysis carried a higher risk of sICH (5.7% vs. 1.6%; OR 3.44; 95% CI 2.04-5.82; P < 0.001) and was not associated with a better prognosis. Subgroup analysis in prospective studies also suggested a poorer functional prognosis and higher mortality in AF patients treated with IVT compared with those who did not receive IVT. Some heterogeneity was present in this meta-analysis. CONCLUSIONS: Acute IS patients with AF had worse outcomes than those without AF after thrombolytic therapy, and had a higher incidence of sICH after thrombolysis than those without thrombolysis. Thrombolysis in ischemic stroke patients with AF should be carefully considered based on clinical factors such as NIHSS score, age, and the type of AF.
No takes yet. Share an insight, caveat, or question.
Hu et al. (2021) conducted a meta-analysis in Acute ischemic stroke with atrial fibrillation (n=8,509). Atrial fibrillation vs. Non-atrial fibrillation was evaluated on Modified Rankin Scale (mRS) score of 0-1 at 90 days (OR 0.59, 95% CI 0.43-0.81, p=<0.001). In patients receiving intravenous thrombolysis for acute ischemic stroke, atrial fibrillation was associated with a lower proportion of excellent functional outcomes at 90 days compared to those without atrial fibrillation.
Synapse has enriched 10 related papers. Consider them for comparative context: